San Diego-based TRACON Pharmaceuticals, a biopharmaceutical company, is dedicated to developing and commercializing cutting-edge cancer therapeutics in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody that fights soft tissue sarcoma, as well as YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody that targets various cancer indications. TRACON Pharmaceuticals is also advancing TRC102, a small molecule that is currently undergoing Phase II clinical trials for mesothelioma treatment, and Phase I clinical trials to treat solid tumors and lymphomas, lung cancer, and glioblastoma. Additionally, the company is developing TJ004309, a CD73 antibody that is currently in Phase I clinical development for the treatment of solid tumors. TRACON Pharmaceuticals has entered into collaboration and license agreements with Jiangsu Alphamab Biopharmaceuticals and 3D Medicines, among others, for the development of envafolimab and TJ004309. The company has also partnered with Case Western Reserve University and the National Cancer Institute to advance TRC102. TRACON Pharmaceuticals was founded in 2004, previously known as Lexington Pharmaceuticals, and changed its name to TRACON Pharmaceuticals, Inc. in March 2005.